Recently, Keylights (Shenzhen) Technology Co., LTD. (hereinafter referred to as Keylights) announced the completion of nearly 100 million yuan of series B financing, which was led by Lucion Venture Capital, and followed by Hanchi Venture Capital. After the financing, Keylights will further accelerate the commercialization of a full range of chemiluminescence, immunofluorescence, molecular diagnosis and other in vitro diagnostic instruments, provide ultra-stable, high-performance, cost-effective products and CDMO services for both domestic and international customers, and become the leading independent brand of in vitro diagnostic instruments and global suppliers for CDMO.
Keylights (Shenzhen) was established in April 2021, and its holding subsidiary Keysmile (Chongqing) was established in September 2013. The company is a leading R&D and manufacturing enterprise of in vitro diagnostic instruments in China, providing customers with customized products and services for in vitro diagnostic instruments. It covers the whole cycle of whole machine development, core module development, design transformation, product registration, precision manufacturing, after-sales service, etc.
Keylights has become the core partner of a number of listed companies and companies to be listed, and its products have covered more than 800 well-known first-class hospitals, head third-party medical examination institutions, more than 2,000 other medical institutions. Besides, Keylights, with a global total installed capacity of more than 5,000 units, has successfully installed instruments in Germany, France, Spain, the United States, Brazil, India, Peru, Nepal and other countries. Keylights has an open chemiluminescence analytical instrument platform with completely independent intellectual property rights. Based on the advantages of automatic control technology platform, Keylights wholeheartedly provides diagnostic reagent manufacturers and scientific researchers with customized development of chemiluminescence instruments, and provides commissioned research and development for other analytical instruments, such as immunofluorescence, molecular diagnosis.
In the field of chemiluminescence instrument, Keylights has currently laid out more than 10 products such as SMART 500, SMART 6500, Venus 100, 300, 500, 6000, 9000, with a variety of speed measurement products between 120T/h and 900T/h, which support multiple parallel operation, so that the diversified needs of customers can be met. The ultra-high speed chemiluminescence instrument Venus 9000, which was certified in September 2023, possesses the world’s leading ultra-high speed and the advantage of small size, with 4 connections reaching 3600T/h.
For this financing, Yu Nong, founder and CEO of Keylights, said that,
“The completion of this financing in the period of both industrial adjustment and winter of capital is a high recognition by business partners and investment institutions of Keylights’s strategic planning, technical capabilities, product quality and team execution. We will be committed to developing technical capabilities and product capabilities in the tide of cooperation in the in vitro diagnostic industry, and continue to provide high-quality and cost-effective products and services. Therefore, we can help our business partners improve efficiency and competitiveness, and we can help them achieve business success, and contribute to the health care of all mankind.”
Qiu Fang, deputy general manager of Lucion Venture Capital, said that,
“Lucion Venture Capital, as a state-owned professional venture capital institution, has always upheld the form of venture capital to support the localization and export of high-end medical devices and products, and enhance the competitiveness and global influence of domestic medical device enterprises. Keylights has 10 years of accumulation in the field of chemiluminescence instrument, layout of a variety of products to meet the diversified and differentiated needs of customers, and the cumulative installed capacity of more than 5,000 units. Keylights has grown into a leading domestic CDMO enterprise for IVD instrument and an important partner in this industry. Lucion invests in Keylights, which is an important part of the investment in the field of life science tools. Lucion will support Keylights to become a more influential CDMO enterprise for IVD instrument.”
Jin Yichen, partner of Hanchi Venture Capital, said that,
“As a leading CDMO supplier of in vitro diagnostic instruments, Keylights has platformized and serialized products, which have been verified and recognized by the domestic market, while strengthening the export and laying out the international market. With the continuous development of the IVD industry, the degree of specialization will continue to improve, and the industrial division of labor will become clearer, and Keylights will show a greater value in the industry. Hanchi Ventures will support Keylights to become a platform-capable CDMO provider for IVD instrument.”
About Lucion Venture Capital
Lucion Venture Capital is the largest and the most influential professional venture capital institution in Shandong Province controlled by Shandong Lucion Investment Holding Group Co., LTD. It is the first venture capital institution listed in the domestic capital market (stock code :600783.SH). Since its establishment, which is more than 20 years, the management and operation of various funds has reached more than 40, and the fund scale is about 20 billion yuan, covering the medical health, civil-military integration, advanced manufacturing, electronic information, new energy, new materials and other subdivided industries. Lucion has more than 40 domestic and foreign listed companies. In the field of medical and health care, it has invested in a number of excellent enterprises such as 3D Medicines, Sibionics, APTBIO, ABclonal, WeMed, MDHC, Inscinstech, RemeGen, etc.
About Hanchi Venture Capital
Hanchi focuses on industrial investment in the field of healthcare, and the fund is committed to investing in technological innovation, market-driven and innovative enterprises with commercialization capabilities. Since its establishment in 2023, it has successively invested in excellent enterprises such as Joymed, Xihua, and ForQaly.
